The place of probiotics in human intestinal infections (Q34997147)

5 August 2017

1 reference

title

The place of probiotics in human intestinal infections (English)

1 reference

5 August 2017

0 references

Sullivan A

1

1 reference

5 August 2017

Nord CE

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

International Journal of Antimicrobial Agents

5 August 2017

published in

1 reference

5 August 2017

volume

20

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

313-319

1 reference

Probiotics in man and animals

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Antimicrobial substance from a human Lactobacillus strain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Considerations for use of probiotic bacteria to modulate human health

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Enterococci at the crossroads of food safety?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Probiotic Enterococcus faecium strain is a possible recipient of the vanA gene cluster

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Characterization of Bacillus species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Helicobacter pylori treatment: a role for probiotics?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Empirical antimicrobial therapy for traveler's diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Diarrhea in the returned traveler

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Protection from gastrointestinal diseases with the use of probiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Interactions between rotavirus and gastrointestinal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Oral bacteriotherapy for viral gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Probiotic treatment using Bifidobacterium lactis HN019 reduces weanling diarrhea associated with rotavirus and Escherichia coli infection in a piglet model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Treatment and prevention of antibiotic associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Epidemiology of Clostridium difficile-associated infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

1 reference

7 January 2021

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

New developments in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

Saccharomyces boulardii in maintenance treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900199-1

7 January 2021

10.1016/S0924-8579(02)00199-1

Identifiers

DOI

1 reference

5 August 2017

1 reference